Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Open access
Gansevoort, Ron T., Arici, Mustafa, Benzing, Thomas, Birn, Henrik, Capasso, Giovambattista, Covic, Adrian, Devuyst, Olivier, Drechsler, Christiane, Eckardt, Kai-Uwe, Emma, Francesco, Knebelmann, Bertrand, Le Meur, Yannick, Massy, Ziad A., Ong, Albert C.M., Ortiz, Alberto, Schaefer, Franz, Torra, Roser, Vanholder, Raymond, Więcek, Andrzej, Zoccali, Carmine, Van Biesen, Wim·2016·Nephrology Dialysis Transplantation

Abstract

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfv456

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 255

Metadata

Authors
Gansevoort, R. T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A., Devuyst, O., Drechsler, C., Eckardt, K.-U., Emma, F., Knebelmann, B., Le Meur, Y., Massy, Z. A., Ong, A. C. M., Ortiz, A., Schaefer, F., Torra, R., Vanholder, R., Więcek, A., Zoccali, C., & Van Biesen, W.
Venue
Nephrology Dialysis Transplantation
Published
2016-01-29
Volume
31
Issue
3
Pages
337-348
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2269899460
Cited by
255
References
37
FWCI
25.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. https://app.cochat.ai/papers/10.1093/ndt/gfv456
The paper
Gansevoort, R. T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A., Devuyst, O., Drechsler, C., Eckardt, K.-U., Emma, F., Knebelmann, B., Le Meur, Y., Massy, Z. A., Ong, A. C. M., Ortiz, A., Schaefer, F., Torra, R., Vanholder, R., Więcek, A., . . . Van Biesen, W. (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfv456

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.